|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The chemokine signaling pathway could characterize subtypes of IDH wild-type astrocytomas.
|
29221210 |
2017 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Evidence also supports the conclusion that the vast majority of diffuse gliomas without IDH mutations (IDH-wild-type astrocytomas) behave like IDH-wild-type glioblastomas ("molecular GBM").
|
29775073 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We found 165 IDH1 (72.7%) and 2 IDH2 mutations (0.9%) in 227 diffuse astrocytomas WHO grade II, 146 IDH1 (64.0%) and 2 IDH2 mutations (0.9%) in 228 anaplastic astrocytomas WHO grade III, 105 IDH1 (82.0%) and 6 IDH2 mutations (4.7%) in 128 oligodendrogliomas WHO grade II, 121 IDH1 (69.5%) and 9 IDH2 mutations (5.2%) in 174 anaplastic oligodendrogliomas WHO grade III, 62 IDH1 (81.6%) and 1 IDH2 mutations (1.3%) in 76 oligoastrocytomas WHO grade II and 117 IDH1 (66.1%) and 11 IDH2 mutations (6.2%) in 177 anaplastic oligoastrocytomas WHO grade III.
|
19554337 |
2009 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that CDKN2A testing may provide further clinical aid in lower-grade glioma substratification beyond IDH mutation and 1p19q codeletion status, particularly in IDH/TP53 mutated astrocytomas.
|
25853694 |
2015 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
HPO |
|
|
|
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 have been found to be frequent and early genetic alterations in astrocytomas and oligodendrogliomas.
|
19996293 |
2009 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A discovery cohort of 211 IDH-mutant astrocytic gliomas with an extended observation was subjected to histological review, image analysis, and DNA methylation studies.
|
29687258 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The association between TP53 and IDH mutation was significant in diffuse astrocytomas (P = 0.0018).
|
22136423 |
2012 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Non-canonical IDH mutations were identified in 13/52 (25.0%) grade II gliomas (astrocytomas: 8/31, 25.8%; oligodendrogliomas: 5/21, 23.8%) and in 5/40 (12.5%) grade III gliomas (astrocytomas: 3/25, 12.0%; oligodendrogliomas: 2/15, 13.3%).
|
28748342 |
2017 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
With the advent of molecular genetics, molecular diagnostic testing has been added to histological evaluation in the armamentarium of the pathologist, and the recent World Health Organization (WHO) Classification of Tumors of the Central Nervous System encourages testing for isocitrate dehydrogenase (IDH) gene status in the classification of diffuse astrocytic gliomas.
|
29548048 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Median overall survival of IDH-wildtype TERTp-mutant astrocytomas was 27 mo.
|
30407589 |
2019 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We raise the question whether IDH-wild type high grade astrocytomas without microvascular proliferation or necrosis might best be classified as GBM, even if they lack the histologic hallmarks as required in the current WHO classification.
|
25943888 |
2015 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Mutations in isocitrate dehydrogenase enzyme isoforms 1 (IDH1) and 2 (IDH2) have been identified in many adult astrocytomas and oligodendrogliomas.
|
19915484 |
2009 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
GPR158 promotes glioma stem cell differentiation and induces apoptosis and is highest expressed in the cerebral cortex and in oligodendrogliomas, lower in IDH mutant astrocytomas and lowest in the most malignant form of glioma, IDH wild-type glioblastoma.
|
29720725 |
2018 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Those astrocytomas without IDH mutation tend to have a distinct genotype and a poor prognosis comparable to that of glioblastomas.
|
25975377 |
2015 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We have elucidated molecularly distinct subclasses of lower grade diffuse astrocytic glioma that dictate clinical behavior and show fundamental associations with both IDH mutational status and neuroglial developmental stage.
|
22415316 |
2012 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
False positive mismatch sign was noted in 28.5% (12/42) Group O tumors, but none of the tumors in Group G. A combination of all three factors: age under 40 years at first diagnosis, a tumor size larger than 6 cm and T2-FLAIR mismatch was highly specific for IDH mutant astrocytoma (Group A).
|
30536195 |
2019 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Despite the favorable prognostic factors, including World Health Organization grades II and III astrocytomas and IDH mutations, the outcome was poor.
|
31698124 |
2020 |
|
Astrocytoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
|
26087904 |
2015 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Several investigations have searched a correlation between the BRAF gene fusions alterations and mutations at IDH1 and IDH2 genes in low grade pediatric astrocytomas.
|
24532263 |
2014 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We analyzed markers, including IDH mutation(IDHmut), 1p19q codeletion(1p19qcodel), ATRX expression loss(ATRX loss) and p53 overexpression, and outcomes in 159 patients with WHO grade II oligodendroglioma, oligoastrocytoma, and astrocytoma (2003-2012).
|
26210286 |
2015 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Thus, the question remains whether the established histopathological grading criteria for malignant astrocytomas in the absence of an IDH mutation are still important if neither vascular proliferation nor necrosis are detectable.
|
31623667 |
2019 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH mutations were observed in 63.2% of astrocytomas, 73.3% of diffuse oligodendrogliomas and 12.90% of glioblastomas.
|
27268645 |
2016 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH mutation is an important prognostic factor of diffuse astrocytomas.
|
30113684 |
2019 |
|
Astrocytoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Trisomy of chromosome 7 in IDH mutated astrocytoma and PTEN mutations in IDH mutated oligodendroglioma are potential markers of poor prognosis, but require confirmation in larger series.
|
29663171 |
2018 |